J Gynecol Oncol.  2010 Jun;21(2):93-96. 10.3802/jgo.2010.21.2.93.

Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature

• Mabuchi S
• Morishige
• Enomoto T
• Kimura T

• KMID: 2009577
• DOI: http://doi.org/10.3802/jgo.2010.21.2.93

Abstract

OBJECTIVE
The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer.
METHODS
We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint.
RESULTS
Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%.
CONCLUSION
TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.

Keyword

Stage IVb; Cervical cancer; Carboplatin; Paclitaxel

MeSH Terms

Carboplatin
Gynecology
Humans
Obstetrics
Paclitaxel
Retrospective Studies
Uterine Cervical Neoplasms
Carboplatin
Paclitaxel

Reference

1. Omura GA. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. J Natl Cancer Inst Monogr. 1996. 21:123–126.

2. Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kohno T, et al. Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma. Oncol Rep. 2008. 19:497–503.

3. National Comprehensive Cancer Network. NCCN practice guideline in oncology 2008 [Internet]. c2010. cited 2010 Mar 20. Fort Washington: National Comprehensive Cancer Network;Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

4. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004. 22:3113–3119.

5. McGuire WP 3rd, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989. 7:1462–1468.

6. Barbera L, Thomas G. Management of early and locally advanced cervical cancer. Semin Oncol. 2009. 36:155–169.

7. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007. 25:2966–2974.

8. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005. 23:4626–4633.

9. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009. 27:4649–4655.

10. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010. 116:44–49.

11. Coleman RL. The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials. Gynecol Oncol. 2008. 110:3 Suppl 2. S77–S80.

12. Mabuchi S, Morishige K, Fujita M, Tsutsui T, Sakata M, Enomoto T, et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol. 2009. 113:200–204.

13. Sit AS, Kelley JL, Gallion HH, Kunschner AJ, Edwards RP. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest. 2004. 22:368–373.

14. Secord AA, Havrilesky LJ, Carney ME, Soper JT, Clarke-Pearson DL, Rodriguez GC, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol. 2007. 12:31–36.

15. Piver MS, Ghamande SA, Eltabbakh GH, O'Neill-Coppola C. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix: a phase II study. Gynecol Oncol. 1999. 75:334–337.

16. Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol. 2005. 98:54–58.

17. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, et al. A comparison of cisplatin/paclitaxel and carboplatin/ paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007. 105:299–303.

18. US National Institutes of Health. ClinicalTrials.gov: a randomized phase III trial of paclitaxel plus cisplatin versus paclitaxel plus carboplatin in stage IVb, persistent, or recurrent cervical cancer [Internet]. cited 2010 Mar 20. Rockville: US National Institutes of Health;Available from: http://www.clinicaltrials.gov.